Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 6/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MRGPRX1 | Q96LB2 | 2/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.36 |
| ▸ | CASR | P41180 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22957928 | 0.90 | NTRK1 (0.41) | NTRK1MEN1KMT2AADRA1DADRA1A | |
| SCHEMBL22957691 | 0.88 | NTRK1 (0.44) | NTRK1CYP1A2ADRA1DADRA1AADRA1B | |
| SCHEMBL22957885 | 0.84 | SLC6A4 (0.39) | HTR2ASLC6A4KDM4ETDP1POLB | |
| SCHEMBL22957698 | 0.80 | SLC6A4 (0.56) | NTRK1HTR2ASLC6A4RIPK1KCNH2 | |
| SCHEMBL25938010 | 0.79 | SLC6A2 (0.42) | NTRK1SLC6A4ALDH1A1 | |
| SCHEMBL22957906 | 0.76 | MEN1 (0.39) | MEN1CYP1A2CYP2C19KMT2AADRA1D | |
| SCHEMBL24180218 | 0.76 | PPARG (0.40) | NTRK1MEN1CYP1A2KMT2AKDM4E | |
| SCHEMBL22957926 | 0.75 | NTRK1 (0.43) | NTRK1MEN1CYP1A2KMT2AHTR2A | |
| SCHEMBL22957866 | 0.74 | HTR2A (0.37) | HTR2ASLC6A4KDM4ETDP1KCNH2 | |
| SCHEMBL28613921 | 0.73 | ALDH1A1 (0.44) | NTRK1MEN1KMT2AHTR2ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10913738-B2 | Aminotriazolopyridines as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913738-B2 | Aminotriazolopyridines as kinase inhibitors | RIPK1, RIPK3, RIPK4 | NTRK1 448/4885MEN1 3915/4885CYP1A2 2727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.